Bipartisan members of the U.S. House have introduced legislation aimed at bolstering Medicare beneficiaries’ access to diagnostic imaging agents.

Currently, the federal payment program only reimburses for radiopharmaceuticals through a packaged system. But this can create a “significant barrier” for those who need newer nuclear imaging agents, advocates note.